A new study by US Food and Drug Administration scientists has found a link to some of the newer diabetes drugs to a “flesh-eating” genital disease.
The FDA announced that SGLT2 inhibitors are linked to a rare but life-threatening bacterial infection.
The infection can spread rapidly killing skin tissue as it grows
RT reports: Symptoms of the disease known as ‘Fournier gangrene’ include pain, redness and a foul odor in the genital area. Alarmingly, the infection starts by attacking your genital or anal region, but can also spread rapidly and kill other body tissue along the way.
The rare infection concerns people taking a newer class of diabetes medications known as SGLT2 inhibitors, according to FDA scientists who recently published their findings on the issue.
The drugs were introduced to the market in March 2013 and, as of January 2019, have been linked to 55 people with Fournier gangrene, all of whom required hospitalization and three of whom died from the disease. In comparison, researchers found only 19 cases of the disease in patients taking other diabetes medications from 1984 to 2019.
As disturbing as the possible side effects may be, diabetes experts are keen to stress that the infections affect a very small percentage of diabetics. “The benefits of these medications outweigh the risks,” Dr Joel Zonszein, director of the clinical diabetes center at Montefiore Medical Center in New York City, told Medical Xpress.
“Fournier gangrene is a rare event,”said study author Dr Susan Bersoff-Matcha.
Meanwhile, one of the manufacturers of SGLT2 inhibitors, Boehringer Ingelheim, said it remains “confident in the positive benefit-risk profile” of their medication.
Patients taking SGLT2 inhibitors are advised by the FDA to immediately seek medical attention if they experience tenderness, redness, or swelling of the genital region.